{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:05:01Z","timestamp":1780409101513,"version":"3.54.1"},"reference-count":145,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hematological malignancies encompass a broad spectrum of relatively rare cancers with diverse biological and clinical characteristics that are capable of affecting individuals across all age groups, though certain subtypes show a predilection for specific age ranges. Advances in next-generation sequencing have greatly enhanced our understanding of the molecular and genetic basis of these diseases, while epigenetic, transcriptional, and proteomic analyses have further clarified their pathogenesis. These developments have shaped the classification and treatment of lymphoma. Updated classification frameworks which include the identification of clinically relevant molecular targets have opened the door to a number of targeted agents, each designed to exploit specific vulnerabilities within malignant cells, while stem cell transplantation continues to offer curative potential for eligible patients, with improving safety profiles over time. CAR-T-cell therapy has been extended to multiple blood cancer indications, achieving lasting remissions in patients with previously exhausted treatment options. Bispecific antibodies have further broadened the immunotherapy landscape by redirecting the body\u2019s own T cells against tumor cells, offering a readily available alternative that overcomes many of the practical limitations associated with CAR-T-cell production. The ability to combine these strategies has fundamentally changed what is achievable in blood cancer treatment, with long-term remission now a realistic goal for many patients. This review seeks to outline the core molecular mechanisms underlying lymphoma and leukemia, evaluate currently approved treatment options, discuss significant ongoing clinical trials with practice-changing potential, and explore the prospect of chemotherapy-free approaches in carefully selected patient groups.<\/jats:p>","DOI":"10.3390\/ijms27115026","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:45:08Z","timestamp":1780404308000},"page":"5026","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Insights and Novel Therapies for Lymphoproliferative Disorders"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9873-900X","authenticated-orcid":false,"given":"Shucen","family":"Wan","sequence":"first","affiliation":[{"name":"Penn State Milton S. Hershey Medical Center, 500 University Dr, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9859-151X","authenticated-orcid":false,"given":"Seema","family":"Naik","sequence":"additional","affiliation":[{"name":"Penn State Milton S. Hershey Medical Center, 500 University Dr, Hershey, PA 17033, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3324\/haematol.2022.282442","article-title":"Advances in next-generation sequencing and emerging technologies for hematologic malignancies","volume":"109","author":"Kwon","year":"2024","journal-title":"Haematologica"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1016\/j.bbmt.2020.03.003","article-title":"Myeloablative versus Reduced-Intensity Hematopoietic Cell Transplantation in Myelodysplastic Syndromes: Systematic Review and Meta-analysis","volume":"26","author":"Rashidi","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_3","first-page":"1","article-title":"Single-cell technologies and analyses in hematopoiesis and hematological malignancies","volume":"98","author":"Alandes","year":"2021","journal-title":"Exp. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41592-020-01038-7","article-title":"Spatially resolved transcriptomics adds a new dimension to genomics","volume":"18","author":"Larsson","year":"2021","journal-title":"Nat. Methods"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Talotta, D., Almasri, M., Cosentino, C., Gaidano, G., and Moia, R. (2023). Liquid biopsy in hematological malignancies: Current and future applications. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1164517"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cpet.2024.05.008","article-title":"Role of novel quantitative imaging techniques in hematological malignancies","volume":"19","author":"Parghane","year":"2024","journal-title":"PET Clin."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood.2022015849","article-title":"Developing a classification of hematologic neoplasms in the era of precision medicine","volume":"140","author":"Cazzola","year":"2022","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","article-title":"Genomic profiling for clinical decision making in lymphoid neoplasms","volume":"140","author":"Alizadeh","year":"2022","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/bjh.19218","article-title":"The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib","volume":"204","author":"Sartori","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/bloodadvances.2024014707","article-title":"Subgroup analysis of older patients \u226560 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study","volume":"9","author":"Hu","year":"2025","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1200\/JCO-25-00925","article-title":"Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma","volume":"43","author":"Morschhauser","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa2401532","article-title":"Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma","volume":"390","author":"Melani","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Chaudhari, J., and Shah, N.N. (2025). Targeted Therapies and Immunotherapies for Diffuse Large B-Cell Lymphoma. Cancers, 17.","DOI":"10.3390\/cancers17152517"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lica, J.J., Pradhan, B., Safi, K., Jak\u00f3bkiewicz-Banecka, J., and Hellmann, A. (2024). Promising therapeutic strategies for hematologic malignancies: Innovations and potential. Molecules, 29.","DOI":"10.3390\/molecules29174280"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies\u2014BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kamakura, D., Asano, R., and Yasunaga, M. (2021). T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. Pharmaceuticals, 14.","DOI":"10.3390\/ph14111172"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s10238-025-01783-z","article-title":"The epigenetic revolution in hematology: From benchside breakthroughs to clinical transformations","volume":"25","author":"Servatian","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70700","DOI":"10.1111\/jcmm.70700","article-title":"JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In-Patient Developments 2024\u20132025","volume":"29","author":"Shahid","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrc2091","article-title":"The impact of translocations and gene fusions on cancer causation","volume":"7","author":"Mitelman","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"8652","DOI":"10.1038\/sj.onc.1206094","article-title":"BCR\/ABL genes and leukemic phenotype: From molecular mechanisms to clinical correlations","volume":"21","author":"Pane","year":"2002","journal-title":"Oncogene"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1056\/NEJM198211113072002","article-title":"Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin\u2019s lymphoma","volume":"307","author":"Yunis","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Carazzolo, M.E., Moioli, A., and Visco, C. (2025). TP53 Mutations in Mantle Cell Lymphoma: From Backup to Game Changer. J. Clin. Med., 14.","DOI":"10.3390\/jcm14238480"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nature14666","article-title":"Non-coding recurrent mutations in chronic lymphocytic leukaemia","volume":"526","author":"Puente","year":"2015","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1038\/s41467-024-47701-x","article-title":"EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition","volume":"15","author":"Romero","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1038\/s41467-024-47012-1","article-title":"Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-020-00437-8","article-title":"CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S1074-7613(00)80015-1","article-title":"CREB Regulates MHC Class II Expression in a CIITA-Dependent Manner","volume":"10","author":"Moreno","year":"1999","journal-title":"Immunity"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Schmid, V.K., and Hobeika, E. (2024). B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1339620"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2012-05-423194","article-title":"Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia","volume":"120","author":"Wiestner","year":"2012","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1186\/s12964-025-02468-6","article-title":"B-cell receptor signaling and microenvironment crosstalk in mantle cell lymphoma","volume":"23","author":"Quaglia","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e7005","DOI":"10.1002\/cam4.7005","article-title":"A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88mut\/CD79Bmut diffuse large B-cell lymphoma","volume":"13","author":"Deng","year":"2024","journal-title":"Cancer Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"107622","DOI":"10.1016\/j.leukres.2024.107622","article-title":"RCHOP plus BTK inhibitor improves clinical outcomes in double expressor diffuse large B-cell lymphoma, unlike RCHOP plus lenalidomide","volume":"148","author":"Feng","year":"2025","journal-title":"Leuk. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7300","DOI":"10.1038\/s41467-025-62509-z","article-title":"Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: Phase II trial","volume":"16","author":"Strati","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: Review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood.2022017697","article-title":"JAK2V617F allele burden in polycythemia vera: Burden of proof","volume":"141","author":"Moliterno","year":"2023","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune evasion in cancer: Mechanisms and cutting-edge therapeutic approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14712598.8.1.5","article-title":"Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: New concepts in blocking immune suppression","volume":"8","author":"Bowdish","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Fiorcari, S., Maffei, R., Atene, C.G., Potenza, L., Luppi, M., and Marasca, R. (2021). Nurse-Like Cells and Chronic Lymphocytic Leukemia B Cells: A Mutualistic Crosstalk inside Tissue Microenvironments. Cells, 10.","DOI":"10.3390\/cells10020217"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e70372","DOI":"10.1002\/mco2.70372","article-title":"Polarization of Tumor Cells and Tumor-Associated Macrophages: Molecular Mechanisms and Therapeutic Targets","volume":"6","author":"Wei","year":"2025","journal-title":"MedComm"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Zhang, Q., and Sioud, M. (2023). Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087493"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"30347","DOI":"10.1038\/srep30347","article-title":"M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma","volume":"6","author":"Shen","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10238-023-01291-y","article-title":"Macrophages and angiogenesis in human lymphomas","volume":"24","author":"Ribatti","year":"2024","journal-title":"Clin. Exp. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100070","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47-SIRP\u03b1-targeted therapeutics: Status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_59","first-page":"3928","article-title":"Blockade of the CD47\/SIRP\u03b1 checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab","volume":"109","author":"Biedermann","year":"2024","journal-title":"Haematologica"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lin, M., Ma, S., Sun, L., and Qin, Z. (2022). The prognostic value of tumor-associated macrophages detected by immunostaining in diffuse large B cell lymphoma: A meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1094400"},{"key":"ref_62","first-page":"e70631","article-title":"Harnessing Epigenetic Mechanisms to Overcome Immune Evasion in Cancer: The Current Strategies and Future Directions","volume":"16","author":"Panda","year":"2024","journal-title":"Cureus"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Dubois, N., Crompot, E., Meuleman, N., Bron, D., Lagneaux, L., and Stamatopoulos, B. (2020). Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: Direct contact, soluble factors, and extracellular vesicles. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01422"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK C481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood.2023023659","article-title":"Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib","volume":"144","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"ref_66","first-page":"1067","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40164-022-00300-2","article-title":"Next-generation sequencing for MRD monitoring in B-lineage malignancies: From bench to bedside","volume":"11","author":"Deng","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Sperotto, A., Bochicchio, M.T., Simonetti, G., Buccisano, F., Peccatori, J., Piemontese, S., Calistri, E., Ciotti, G., Pierdomenico, E., and De Marchi, R. (2023). Measurable Residual Disease and Clonal Evolution in Acute Myeloid Leukemia from Diagnosis to Post-Transplant Follow-Up: The Role of Next-Generation Sequencing. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020359"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Del Giudice, I., Della Starza, I., De Falco, F., Gaidano, G., and Sportoletti, P. (2024). Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia. Cancers, 16.","DOI":"10.3390\/cancers16112049"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_73","first-page":"e97806","article-title":"An Insight into Clinicopathological Parameters and Prognostic Significance of Double Expressor Diffuse Large B-Cell Lymphoma in a Tertiary Care Center","volume":"17","author":"Lakshminarayanan","year":"2025","journal-title":"Cureus"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Hwang, J., Suh, C., Kim, K., Kim, H., Kim, A.I., Craig, J.W., Chen, K.X., Roberson, J., Guenette, J.P., and Huang, R.Y. (2021). The Incidence and Treatment Response of Double Expression of MYC and BCL2 in Patients with Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13133369"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"oyaf085","DOI":"10.1093\/oncolo\/oyaf085","article-title":"Recent advancements in double-expressor lymphoma: Novel therapeutic approaches and prospects","volume":"30","author":"Zhuo","year":"2025","journal-title":"Oncologist"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12792","article-title":"Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment","volume":"291","author":"Young","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41375-020-0766-4","article-title":"Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL","volume":"35","author":"Hartert","year":"2021","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up","volume":"41","author":"Davies","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7012","DOI":"10.1200\/JCO.2024.42.16_suppl.7012","article-title":"Randomized phase II\/III study of R-CHOP +\/\u2212 venetoclax in previously untreated MYC\/BCL2 double expressor diffuse large B cell lymphoma (DLBCL): Alliance A051701","volume":"42","author":"Abramson","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/j.ccell.2023.08.005","article-title":"Genetically informed therapy for lymphoma: The discomfiting benefit of lumping splits","volume":"41","author":"Hahn","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/bloodadvances.2025016483","article-title":"A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphoma","volume":"9","author":"Akkad","year":"2025","journal-title":"Blood Adv."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2017.76.3656","article-title":"Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study","volume":"36","author":"Cheson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): A multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1200\/JCO.2022.40.16_suppl.7510","article-title":"Zanubrutinib plus obinutuzumab (ZO) versus obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R\/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized ROSEWOOD trial","volume":"40","author":"Zinzani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2021-148778","article-title":"Glofitamab as monotherapy and in combination with obinutuzumab induces high complete response rates in patients (pts) with multiple relapsed or refractory (R\/R) follicular lymphoma (FL)","volume":"138","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2022-158404","article-title":"Odronextamab in patients with relapsed\/refractory (R\/R) follicular lymphoma (FL) grade 1-3a: Results from a prespecified analysis of the pivotal phase II study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1200\/JCO.23.02214","article-title":"Lisocabtagene maraleucel in relapsed\/refractory mantle cell lymphoma: Primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/1078-0432.CCR-13-2175","article-title":"Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome","volume":"20","author":"Alhejaily","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/PAS.0000000000000969","article-title":"Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis","volume":"42","author":"Shimono","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Shin, D.M., Lee, C.H., and Morse, H.C. (2011). IRF8 governs expression of genes involved in innate and adaptive immunity in human and mouse germinal center B cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027384"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"eadk2091","DOI":"10.1126\/sciadv.adk2091","article-title":"IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes","volume":"10","author":"Qiu","year":"2024","journal-title":"Sci. Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/blood-2015-07-659938","article-title":"GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo","volume":"127","author":"Healy","year":"2016","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature13765","article-title":"Loss of signalling via G\u03b113 in germinal centre B-cell-derived lymphoma","volume":"516","author":"Muppidi","year":"2014","journal-title":"Nature"},{"key":"ref_106","first-page":"1472","article-title":"Bispecific antibodies in follicular lymphoma","volume":"110","author":"Nizamuddin","year":"2024","journal-title":"Haematologica"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1007\/s00277-025-06428-5","article-title":"A retrospective cohort study of chimeric antigen receptor T-Cell therapy in follicular lymphoma patients with or without histological transformation","volume":"104","author":"Wang","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e19070","DOI":"10.1200\/JCO.2025.43.16_suppl.e19070","article-title":"Meta-analysis of CAR-T and bispecific antibodies in follicular lymphoma: A comparative efficacy assessment","volume":"43","author":"Mehta","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e2025039","DOI":"10.4084\/MJHID.2025.039","article-title":"Toxicities Associated with CAR-T Cell Therapies","volume":"17","author":"Testa","year":"2025","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_110","first-page":"1","article-title":"CAR T-Cell Therapy Unveiled: Navigating Beyond CRS and ICANS to Address Delayed Complications and Optimize Management Strategies","volume":"16","author":"Ow","year":"2025","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T Cell Therapy: The Efficacy and Toxicity Balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/17474086.2025.2522956","article-title":"Current state-of-the-art of immunotherapy in follicular lymphoma","volume":"18","author":"McKeague","year":"2025","journal-title":"Expert Rev. Hematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: Preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_114","first-page":"637","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_115","first-page":"4055","article-title":"PD-1 blockade with pembrolizumab in relapsed low grade non-Hodgkin lymphoma","volume":"130","author":"Ding","year":"2017","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/bloodadvances.2021006240","article-title":"Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma","volume":"6","author":"Nastoupil","year":"2022","journal-title":"Blood Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1016\/j.clml.2021.12.010","article-title":"Combination of atezolizumab and obinutuzumab in patients with relapsed\/refractory follicular lymphoma and diffuse large B-cell lymphoma: Results from a phase 1b study","volume":"22","author":"Palomba","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41408-021-00539-8","article-title":"Obinutuzumab-atezolizumab-lenalidomide for the treatment of patients with relapsed\/refractory follicular lymphoma: Final analysis of a Phase Ib\/II trial","volume":"11","author":"Morschhauser","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00432-021-03847-5","article-title":"Anti-CD20\u2013atezolizumab\u2013polatuzumab vedotin in relapsed\/refractory follicular and diffuse large B-cell lymphoma","volume":"149","author":"Topp","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e632","DOI":"10.3747\/co.27.7053","article-title":"First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma","volume":"27","author":"Bhella","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): A single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"ref_122","first-page":"3148","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"6364","DOI":"10.1200\/JCO.2005.05.019","article-title":"Pathogenesis of mantle-cell lymphoma: All oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways","volume":"23","author":"Hartmann","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1038\/s41375-024-02375-8","article-title":"Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: Results from the EU-MCL network trials","volume":"38","author":"Khouja","year":"2024","journal-title":"Leukemia"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB\u2013targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"key":"ref_127","first-page":"2247","article-title":"SOX11 augments BCR signaling to drive MCL-like tumor development","volume":"131","author":"Kuo","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/aol.2019.03.01","article-title":"Mantle cell lymphoma pathology update in the 2016 WHO classification","volume":"3","author":"Veloza","year":"2019","journal-title":"Ann. Lymphoma"},{"key":"ref_129","first-page":"1419","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_130","first-page":"2283","article-title":"Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions","volume":"131","author":"Puente","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res."},{"key":"ref_132","first-page":"800","article-title":"Nuclear expression of the non\u2013B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma","volume":"111","author":"Ek","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/leu.2012.72","article-title":"Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease","volume":"26","author":"Royo","year":"2012","journal-title":"Leukemia"},{"key":"ref_134","first-page":"413","article-title":"A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome","volume":"132","author":"Clot","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Phillips, T.J., Dickinson, M., Morschhauser, F., Bachy, E., Crump, M., Trn\u011bn\u00fd, M., Bartlett, N.L., Zaucha, J., Wrobel, T., and Offner, F. (2022). Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma, American Society of Hematology.","DOI":"10.1182\/blood-2022-157777"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7008","DOI":"10.1200\/JCO.2024.42.16_suppl.7008","article-title":"Glofitamab Monotherapy in Patients with Heavily Pretreated Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL): Updated analysis from a phase I\/II study","volume":"42","author":"Phillips","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1200\/JCO.23.02329","article-title":"Durable responses with mosunetuzumab in relapsed\/refractory indolent and aggressive B-cell non-Hodgkin lymphomas: Extended follow-up of a phase I\/II study","volume":"42","author":"Budde","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2023-174956","article-title":"Fixed duration mosunetuzumab plus polatuzumab vedotin has promising efficacy and a manageable safety profile in patients with BTKi relapsed\/refractory mantle cell lymphoma: Initial results from a phase Ib\/II study","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/bloodadvances.2024013586","article-title":"Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma","volume":"9","author":"Roddie","year":"2025","journal-title":"Blood Adv."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s12935-024-03479-y","article-title":"Recent updates on allogeneic CAR-T cells in hematological malignancies","volume":"24","author":"Mansoori","year":"2024","journal-title":"Cancer Cell Int."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5026\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:11:49Z","timestamp":1780405909000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":145,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27115026"],"URL":"https:\/\/doi.org\/10.3390\/ijms27115026","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]}}}